Brookline Capital Markets initiates Exelixis with 'buy' rating

Exelixis

23/12/2024 18:01

** Brookline Capital Markets initiates coverage of 
biotechnology company Exelixis  EXEL.O  with "buy" rating 
    ** Brokerage expects EXEL to develop its commercial drugs
Cabometyx and Cometriq
    ** Says EXEL's total product sales to reach $6.7 bln in 2033
    ** Brokerage sets PT at $40, a ~20.2% upside on stock's last
close
    ** 13 of 23 brokerages rate the stock "buy" or higher, 9
"hold" and 1 "sell"; their median PT is $34 - LSEG data
    ** Including session's moves, stock up ~38.5% YTD

 (Reporting by Prakhar Srivastava in Bengaluru)
 ((Prakhar.srivastava2@thomsonreuters.com))